‘For $1/Day’… Double-Blind Ivermectin Study Reveals COVID Patients Recover More Quickly, Are Less Infectious

‘For $1/Day’… Double-Blind Ivermectin Study Reveals COVID Patients Recover More Quickly, Are Less Infectious

A double-blind Israeli study has concluded that Ivermectin, an inexpensive anti-parasitic widely used since 1981, reduces both the duration and infectiousness of Covid-19, according to the Jerusalem Post. The study, conducted by Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, looked at some 89 eligible volunteers over the age of 18 who had tested positive for coronavirus and were living in state-run Covid-19 hotels. After being divided into two groups, 50% received ivermectin, and 50% received a placebo. Each patient was given the drug for three days in a row, an hour before eating.